Spelling suggestions: "subject:"angiogenesis inn cancer"" "subject:"angiogenesis iin cancer""
1 |
The role of gangliosides in tumourigenesisAimls, Mark Anthony Slevin January 1993 (has links)
No description available.
|
2 |
Regulation of vascular endothelial growth factor receptor-2 in pancreatic and breast cancer cells by Sp proteinsHiggins, Kelly Jean 17 September 2007 (has links)
Vascular endothelial growth factor receptor-2 (VEGFR2) is a key
angiogenic factor, and angiogenesis is an important physiological process
associated with neovascularization, growth, and metastasis of many different
tumors. The mechanism of VEGFR2 gene expression was investigated in
MiaPaCa-2, Panc-1, and AsPC-1 pancreatic cancer cells transfected with a
series of VEGFR2 promoter deletion/mutated constructs, and the results
indicated that the GC-rich âÂÂ60 to âÂÂ37 region of the promoter was essential for
VEGFR2 expression in these cell lines. EMSA and ChIP assays showed that Sp
proteins are expressed and bind to the proximal GC-rich region of the VEGFR2
promoter. RNA interference studies on Sp proteins demonstrated that Sp1, Sp3,
and Sp4 all contributed to VEGFR2 gene/protein expression in pancreatic
cancer cells.
VEGFR2 gene expression was also investigated in ZR-75 and MCF-7
breast cancer cells. ZR-75 cells treated with 10 nM 17b-estradiol (E2) increased
VEGFR2 mRNA levels/protein expression. The VEGFR2 promoter was induced
by E2 in ZR-75 cells, and analysis of the VEGFR2 promoter identified the GC rich -60 to -37 region that was required for E2-mediated transactivation. EMSA
and ChIP assays confirmed that Sp1, Sp3, and Sp4 proteins are expressed in
ZR-75 cells and bind the proximal GC-rich region of the VEGFR2 promoter.
RNA interference was used to determine the relative contributions of Sp proteins
on hormonal regulation of VEGFR2 through ER/Sp complexes, and interestingly,
in ZR-75 cells, hormone-induced activation of VEGFR2 involves ERa/Sp3 and
ERa/Sp4 but not ERa/Sp1.
In MCF-7 cells treated with 10 nM E2, VEGFR2 mRNA levels were
decreased. Analysis of the VEGFR2 promoter revealed that the same GC-rich
region important for E2-mediated upregulation in ZR-75 cells was responsible for
E2-dependent downregulation of VEGFR2 gene expression in MCF-7 cells.
EMSA and ChIP assays confirmed that Sp1, Sp3, and Sp4 proteins are
expressed in MCF-7 cells and bind to the proximal GC-rich region of the
VEGFR2 promoter. RNA interference studies showed that Sp1, Sp3, and Sp4
are involved in the E2-mediated downregulation of VEGFR2 in MCF-7 cells, and
ERa/Sp protein-promoter interactions are accompanied by recruitment of the
corepressor SMRT using the ChIP assay.
|
3 |
Hypoxia and angiogenesis in renal cell carcinomaLawrentschuk, Nathan Leo January 2009 (has links)
Hypoxia is one of the hallmarks of cancer. It was first postulated to occur in solid tumours by Thomlinson and Gray in 1955.1 The presence of hypoxia has been demonstrated in different types of solid tumours.2 Intratumoral hypoxia is caused by the lack of functional blood vessels in proliferating tumour tissue, resulting in low intratumoral oxygen concentrations. If hypoxia is severe or prolonged, cell death occurs.3 Malignant cells can undergo genetic and adaptive changes that allow them to escape from dying of oxygen deprivation. These changes are associated with a more aggressive malignant phenotype 4,5 conferring resistance to radiation 6,7 and chemotherapeutic agents.3,8,9 Hence hypoxia is known to be a key factor responsible for tumour resistance in humans. / Invasive polarographic oxygen sensor measurements have demonstrated hypoxia in solid tumours and it is generally defined to occur at an oxygen tension less than ten mmHg.10 Perhaps of more importance is that hypoxia has been demonstrated to be a prognostic indicator for local control after treatment with radiotherapy in glioma, head and neck and cervical cancers.11-13 It has also been able to predict for survival and the presence of distant metastases in soft tissue sarcomas.14 Finally, the significance of hypoxia in the activation and induction of functional molecules such as hypoxia inducible factors (HIFs) and VEGF, the modulation of gene expression (e.g. carbonic anhydrase IX), increased proto-oncogene levels, activation of nuclear factors and accumulation of other proteins (e.g. TP53) although progressing, is yet to be defined.15,16 / Thus, it is of clinical interest to understand the levels of hypoxia and numbers of hypoxic cell populations in tumours, particularly those resistant to radiation and chemotherapy. In doing so clinicians and researchers may formulate more accurate prognostic information and develop treatments targeting hypoxic cells. Renal cell carcinoma (RCC) is a tumour resistant to radiation and chemotherapy that is yet to have its oxygen status investigated. / Although the “gold standard” of oxygen tension measurement is the Polarographic Oxygen Sensor (POS or Eppendorf pO2 histograph), non-invasive means of measuring oxygen status via imaging, immunohistochemistry or serum tumour markers are more practical. As highlighted by Menon and Fraker, it is imperative that reliable, globally usable, and technically simplistic methods be developed to yield a consistent, comprehensive, and reliable profile of tumour oxygenation. Until newer more reliable techniques are developed, existing independent techniques or appropriate combinations of techniques should be optimized and validated using known endpoints in tumour oxygenation status and/or treatment outcomes.17 / Hanahan and Weinberg 18 surmised that the field of cancer research has largely been guided by a reductionist focus on cancer cells and the genes within them- a focus that has produced an extraordinary body of knowledge. Looking forward in time, they believe that progress in cancer research would come from regarding tumours as complex tissues in which mutant cancer cells have conscripted and subverted normal cell types (endothelial cells, immune cells, fibroblasts) to serve as active collaborators in their neoplastic agenda. The interactions between the genetically altered malignant cells and these supporting coconspirators will prove critical to understanding cancer pathogenesis and to the development of novel, effective therapies.18 / Essentially, the background outlined here not only highlights the core aim of this thesis: to better understand the oxygen status of renal cell carcinoma and the relationship of this to angiogenesis so that better targeted therapies may be pursued in the future; but it also places this research in the context of the future proposed by Hanahan and Weinberg,18 by clearly focusing on collaborators in the neoplastic agenda, rather than just tumour cells themselves, to better understand RCC.
|
4 |
A WHOLE CELL BASED BIOSENSOR FOR MONITORING PHYSIOLOGICAL TOXINS AND EARLY SCREENING OF CANCERGhosh, Gargi 01 January 2008 (has links)
Recently a whole cell based biosensor has been developed in our laboratory that consists of a monolayer of human umbilical vein endothelial cells (HUVECs) on the asymmetric cellulose triacetate (CTA) membrane of an ion selective electrode (ISE). When a confluent cell monolayer is formed across the membrane, response from the sensor is inhibited due to inhibited ion transport across the membrane. When the cell based biosensor is exposed to permeability modifying agents, the permeability across the cell monolayer is altered facilitating more ion transport and as a result the response from the sensor increases. This sensor response can be related to the concentration of these agents. One objective of this research was to investigate the ability of the sensor to detect a physiological toxin, alpha toxin from Staphylococcus aureus. Studies demonstrated that the biosensor can detect 0.1ng/ml alpha toxin. Considering the fact that the concentration of this toxin is 100-250 ng/ml in whole blood in humans, this biosensor has the ability to act as the diagnostic tool for staphylococcal diseases. Another part of this research was to investigate the ability of the biosensor to measure angiogenesis by measuring the changes in permeability induced by cytokines such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF) and tumor necrosis factor andamp;aacute; (TNF- andamp;aacute;) individually and in combination. The sensor response was then compared with the common in vitro assays for angiogenesis. The study demonstrated that at the concentrations studied the sensor response in the presence of cytokines was much higher than that observed for other angiogenesis assays, thereby bolstering the potential of the biosensor to act as a quick screening tool for angiogenesis. Furthermore, epithelial cell based sensor responses to the same cytokines were compared with the responses from endothelial cell based sensor and the mechanisms behind the increased sensor response were elucidated. Finally, to investigate the ability of the sensor to screen cancer, the biosensor was exposed to the serum from healthy individuals and cancer patients. The results showed that the sensor can distinguish between healthy individuals and cancer patients and the results correlate with the stages of cancer.
|
5 |
Angiogenesis in human lung tumoursFerguson, Mary L. January 2008 (has links)
Angiogenesis, the growth of new blood vessels, is vital to tumour growth. Prevailing dogma has been that tumours cannot grow without angiogenesis. Based on this premise, anti-angiogenic drugs are used clinically. However, the principle of angiogenesis as an absolute requirement for tumour growth has been challenged with reports that many tumours are entirely or partially non-angiogenic. This study describes and quantifies characteristics of non-angiogenic non-small cell lung tumours, demonstrates non-angiogenic growth in small-cell/neuroendocrine lung tumours and investigates the underlying pathogenetic processes by comparison with angiogenic lung tumours. Hypoxia is an important stimulus for angiogenesis. Differences in response to hypoxia may determine whether a tumour produces new vessels. In order to test this, levels of. necrosis, often considered a surrogate marker of hypoxic stress, were quantified but no difference in quantity of necrosis was found Moreover, immunohistochemical investigation of hypoxia and angiogenesis factors provided no unambiguous explanation for the differences in angiogenesis. Significant differences were seen, however, in fibrosis and inflammation, which were both greater in angiogenic tumours. Differences were greater for lymphocytes rather than cells of the ‘innate’ immune system. This provided an alternative hypothesis: angiogenesis occurs during wound healing and in the growth of granulation tissue, so it is possible that tumour angiogenesis is a response to factors produced by immune cells rather than the tumour itself. A tumour’s angiogenic status may, therefore, be determined by the response it provokes from the immune system. Further work to test this theory would compare levels of immunogenic factors such as Tumour Necrosis Factor and tumour cell surface antigens such as the HLA class I molecules. The study concludes with an investigation into the molecular basis of non-angiogenic growth using the technique of comparative genomic hybridisation (CGH) which allows amplifications and deletions of areas of DNA to be calculated. High-resolution array CGH was evaluated against conventional CGH, and the results compared with previous RNA studies from our laboratory. These revealed a set of genes with consistent changes in both RNA and DNA, several of which form part of known angiogenic and inflammatory pathways.
|
6 |
Anticancer Activity and Mechanisms of Action of New Chimeric EGFR/HDAC-InhibitorsGoehringer, Nils, Biersack, Bernhard, Peng, Yayi, Schobert, Rainer, Herling, Marco, Ma, Andi, Nitzsche, Bianca, Höpfner, Michael 24 January 2024 (has links)
New chimeric inhibitors targeting the epidermal growth factor (EGFR) and histone deacetylases
(HDACs) were synthesized and tested for antineoplastic efficiency in solid cancer (prostate
and hepatocellular carcinoma) and leukemia/lymphoma cell models. The most promising compounds,
3BrQuin-SAHA and 3ClQuin-SAHA, showed strong inhibition of tumor cell growth at
one-digit micromolar concentrations with IC50 values similar to or lower than those of clinically
established reference compounds SAHA and gefitinib. Target-specific EGFR and HDAC inhibition
was demonstrated in cell-free kinase assays andWestern blot analyses, while unspecific cytotoxic
effects could not be observed in LDH release measurements. Proapoptotic formation of reactive
oxygen species and caspase-3 activity induction in PCa and HCC cell lines DU145 and Hep-G2 seem
to be further aspects of the modes of action. Antiangiogenic potency was recognized after applying
the chimeric inhibitors on strongly vascularized chorioallantoic membranes of fertilized chicken eggs
(CAM assay). The novel combination of two drug pharmacophores against the EGFR and HDACs in
one single molecule was shown to have pronounced antineoplastic effects on tumor growth in both
solid and leukemia/lymphoma cell models. The promising results merit further investigations to
further decipher the underlying modes of action of the novel chimeric inhibitors and their suitability
for new clinical approaches in tumor treatment.
|
Page generated in 0.3654 seconds